San Diego County's Premier Collective for Medical Grade Marijuana Clones and Cannabis Seeds
Cart - $0.00
Call Us: 760-687-9978

The U.S. Patent Office issued patent #6630507 to the U.S. Health and Human Services filed on 2/2/2001. The patent lists the use of certain cannabinoids found within the cannabis sativa plant as useful in certain neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and HIV dementia.      


US Patent 6,630,507  Cannabinoids as Antioxidants and Neuroprotectants 

“Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH.sub.3, and COCH.sub.3. ##STR1##”
 
 

 Since cannabis sativa (marijuana) contains compounds recognized and endorsed by an agency of the U.S. government – Why is it that marijuana remains listed as a Federal Schedule One drug? The issuance of patent #6630507 is a direct contradiction of the governments own definition for classification of a Schedule 1 drug.  

 

www.uspatent6630507.com